Non-covalent proteasome inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 22, 2013, Pages 4115-4130

  Kaffy, Julia ^a   Bernadat, Guillaume ^a   Ongeri, Sandrine ^a  

^a UNIVERSITÉ PARIS SUD   (France)

Author keywords

Anti cancer drugs; Natural peptides; Non covalent inhibitors; Proteasome; Pseudopeptides; Small synthetic molecules

Indexed keywords

AAPTAMINE; ACLARUBICIN; ACRIDINE DERIVATIVE; ARGYRIN; BENZENE DERIVATIVE; BETULIC ACID; BIPHENYL DERIVATIVE; CYCLOPEPTIDE; DIPEPTIDE; GLIOTOXIN; HYDROXYUREA; KENDOMYCIN; LIPOPEPTIDE; MACROLIDE; NATURAL PRODUCT; OXINDOLE; PHENOL DERIVATIVE; PORPHYRIN; PROTEASOME INHIBITOR; PSEUDOPEPTIDE; QUINONE DERIVATIVE; SCYTONEMIDE; STATINE DERIVATIVE; SULFONAMIDE; TRIPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PEPTIDE FRAGMENT; PROTEASOME;

ARTICLE; DIASTEREOISOMER; ENANTIOMER; FERMENTATION; HUMAN; IC50; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; ANIMAL; DRUG EFFECT; NEOPLASM; REVIEW; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84885422353     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319220016     Document Type: Article

References (130)

1. Etlinger JD, Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci U S A 1977; 74: 54-8.
2. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-60.
3. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon. acidophilum at 3.4 A resolution. Science 1995; 268: 533-9.
4. Borissenko L, Groll M. 20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development. Chem Rev 2007; 107: 687-717.
5. Groll M, Ditzel L, Löwe J, et al. Structure of 20S proteasome from yeast at 2.4Å resolution. Nature 1997; 386: 463-71.
6. Kwon YD, Nagy I, Adams PD, Baumeister W, Jap BK. Crystal Structures of the Rhodococcus Proteasome with and without its Pro-peptides: Implications for the Role of the Pro-peptide in Proteasome Assembly. J Mol Biol 2004; 335: 233-45.
7. Hu G, Lin G, Wang M, et al. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol Microbiol 2006; 59: 1417-28.
8. Unno M, Mizushima T, Morimoto Y, et al. The Structure of the Mammalian 20S Proteasome at 2.75 Å Resolution. Structure 2002; 10: 609-18.
9. Huber EM, Basler M, Schwab R, et al. Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity. Cell 2012; 148: 727-38.
10. Luy B. Approaching the Megadalton: NMR Spectroscopy of Protein Complexes. Angew Chem Int Ed Engl 2007; 46: 4214-6.
11. Religa TL, Sprangers R, Kay LE. Dynamic Regulation of Archaeal Proteasome Gate Opening As Studied by TROSY NMR. Science 2010; 328: 98-102.
12. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E, Martin A. Complete subunit architecture of the proteasome regulatory particle. Nature 2012; 482: 186-91.
13. Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. BBA. Molecular cell research 2004; 1695: 33-44.
14. Groll M, Heinemeyer W, Jäger S, et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study. Proc Natl Acad Sci U S A 1999; 96: 10976-83.
15. Groll M, Larionov OV, Huber R, Meijere A de. Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation. Proc Natl Acad Sci U S A 2006; 103: 4576-9.
16. Korotkov VS, Ludwig A, Larionov OV, Lygin AV, Groll M, de Meijere A. Synthesis and biological activity of optimized belactosin C congeners. Org Biomol Chem 2011; 9: 7791.
17. Meiners S, Ludwig A, Stangl V, Stangl K. Proteasome inhibitors: Poisons and remedies. Med Res Rev 2008; 28: 309-27.
18. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-60.
19. Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010; 10: 232-56.
20. D’Alessandro A, Pieroni L, Ronci M, D’Aguanno S, Federici G, Urbani A. Proteasome inhibitors therapeutic strategies for cancer. Recent Pat Anticancer Drug Discov 2009; 4: 73-82.
21. Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 1999; 2: 215-23.
22. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29, Supplement 1: 3-9.
23. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5: 18.
24. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Curr Cancer Drug Targets 2011; 11: 239-53.
25. Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21: 30-6.
26. Molineaux SM. Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer. Clin Cancer Res 2012; 18: 15-20.
27. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-59.
28. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15: 243-9.
29. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.
30. Huber EM, Groll M. Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development. Angew Chem Int Ed Engl 2012; 51: 8708-20.
31. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome Inhibitors: An Expanding Army Attacking a Unique Target. Chem Biol 2012; 19: 99-115.
32. Kisselev AF. Joining the Army of Proteasome Inhibitors. Chem Biol 2008; 15: 419-21.
33. García-Echeverría C. Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells. Int J Pept Res Ther 2006; 12: 49-64.
34. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739-58.
35. Hideshima T, Richardson P, Chauhan D, et al. The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells. Cancer Res 2001; 61: 3071-6.
36. Williamson MJ, Blank JL, Bruzzese FJ, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 2006; 5: 3052-61.
37. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593-9.
38. Leung D, Abbenante G, Fairlie DP. Protease Inhibitors: Current Status and Future Prospects. J Med Chem 2000; 43: 305-41.
39. Sanderson PEJ. Small, noncovalent serine protease inhibitors. Med Res Rev 1999; 19: 179-97.
40. Beck P, Dubiella C, Groll M. Covalent and non-covalent reversible proteasome inhibition. Biol Chem 2012; 393: 1101-1020.
41. Krahn D, Ottmann C, Kaiser M. Macrocyclic proteasome inhibitors. Curr Med Chem 2011; 18: 5052-60.
42. Koguchi Y, Kohno J, Nishio M, et al. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sac. TC 1093. Taxonomy, production, isolation, and biological activities. J Antibiot (Tokyo) 2000; 53: 105-9.
43. Kohno J, Koguchi Y, Nishio M, et al. Structures of TMC-95A-D: Novel Proteasome Inhibitors from Apiospora montagnei Sac. TC 1093. J Org Chem 2000; 65: 990-5.
44. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001; 311: 543-8.
45. Kaiser M, Groll M, Renner C, Huber R, Moroder L. The Core Structure of TMC-95A Is a Promising Lead for Reversible Proteasome Inhibition. Angew Chem Int Ed Engl 2002; 41: 780-3.
46. Yang Z-Q, Kwok BHB, Lin S, Koldobskiy MA, Crews CM, Danishefsky SJ. Simplified Synthetic TMC-95A/B Analogues Retain the Potency of Proteasome Inhibitory Activity. ChemBioChem 2003; 4: 508-13.
47. Kaiser M, Groll M, Siciliano C, et al. Binding Mode of TMC-95A Analogues to Eukaryotic 20S Proteasome. ChemBioChem 2004; 5: 1256-66.
48. Inoue M, Zhai H, Sakazaki H, Furuyama H, Fukuyama Y, Hirama M. TMC-95A, a reversible proteasome inhibitor, induces neurite outgrowth in PC12 cells. Bioorg Med Chem Lett 2004; 14: 663-5.
49. For a review, see: Coste A, Couty F, Evano G. TMC-95A-D and analogues: Chemistry and biology. C R Chimie 2008; 11: 1544-73.
50. Lin S, Yang Z-Q, Kwok BHB, Koldobskiy M, Crews CM, Danishefsky SJ. Total Synthesis of TMC-95A and -B via a New Reaction Leading to Z-Enamides. Some Preliminary Findings as to SAR. J Am Chem Soc 2004; 126: 6347-55.
51. Inoue M, Sakazaki H, Furuyama H, Hirama M. Total Synthesis of TMC-95A. Angew Chem Int Ed Engl 2003; 42: 2654-7.
52. Albrecht BK, Williams RM. A concise, total synthesis of the TMC-95A/B proteasome inhibitors. Proc Natl Acad Sci U S A 2004; 101: 11949-54.
53. Sasse F, Steinmetz H, Schupp T, et al. Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 2002; 55: 543-51.
54. Vollbrecht L, Steinmetz H, Hofle G, et al. Argyrins, immunosuppressive cyclic peptides from myxobacteria. II. Structure elucidation and stereochemistry. J Antibiot (Tokyo) 2002; 55: 715-21.
55. Bülow L, Nickeleit I, Girbig A-K, et al. Synthesis and Biological Characterization of Argyrin F. ChemMedChem 2010; 5: 832-6.
56. Stauch B, Simon B, Basile T, et al. Elucidation of the Structure and Intermolecular Interactions of a Reversible Cyclic-Peptide Inhibitor of the Proteasome by NMR Spectroscopy and Molecular Modeling. Angew Chem Int Ed Engl 2010; 49: 3934-8.
57. Nickeleit I, Zender S, Sasse F, et al. Argyrin A Reveals a Critical Role for the Tumor Suppressor Protein p27kip1 in Mediating Antitumor Activities in Response to Proteasome Inhibition. Cancer Cell 2008; 14: 23-35.
58. McConkey DJ. A Novel Role for a Familiar Protein in Apoptosis Induced by Proteasome Inhibition. Cancer Cell 2008; 14: 1-2.
59. Wu W, Li Z, Zhou G, Jiang S. Total synthesis of argyrins A and E. Tetrahedron Lett 2011; 52: 2488-91.
60. Ley SV, Priour A. Total Synthesis of the Cyclic Peptide Argyrin B. Eur J Med Chem 2002; 2002: 3995-4004.
61. Bhat UG, Halasi M, Gartel AL. FoxM1 Is a General Target for Proteasome Inhibitors. PLoS ONE 2009; 4: e6593.
62. Bhat UG, Halasi M, Gartel AL. Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells. PLoS ONE 2009; 4: e5592.
63. Pandit B, Bhat UG, Gartel AL. Proteasome inhibitory activity of thiazole antibiotics. Cancer Biol Ther 2011; 11: 43-7.
64. Schoof S, Pradel G, Aminake MN, et al. Antiplasmodial Thiostrepton Derivatives: Proteasome Inhibitors with a Dual Mode of Action. Angew Chem Int Ed Engl 2010; 49: 3317-21.
65. Krunic A, Vallat A, Mo S, Lantvit DD, Swanson SM, Orjala J. Scytonemides A and B, Cyclic Peptides with 20S Proteasome Inhibitory Activity from the Cultured Cyanobacterium Scytonema hofmanii. J Nat Prod 2010; 73: 1927-32.
66. Agerberth B, Lee J-Y, Bergman T, et al. Amino acid sequence of PR-39. Eur J Biochem 1991; 202: 849-54.
67. Gao Y, Lecker S, Post MJ, et al. Inhibition of ubiquitin-proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000; 106: 439-48.
68. Bao J, Sato K, Li M, et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation. Am J Physiol Heart Circ Physiol 2001; 281: H2612-H2618.
69. Gaczynska M, Osmulski PA, Gao Y, Post MJ, Simons M. Prolineand Arginine-Rich Peptides Constitute a Novel Class of Allosteric Inhibitors of Proteasome Activity. Biochemistry 2003; 42: 8663-70.
70. Anbanandam A, Albarado DC, Tirziu DC, Simons M, Veeraraghavan S. Molecular Basis for Proline- and Arginine-Rich Peptide Inhibition of Proteasome. J Mol Biol 2008; 384: 219-27.
71. Waring P, Eichner RD, Müllbacher A, Sjaarda A. Gliotoxin induces apoptosis in macrophages unrelated to its antiphagocytic properties. J Biol Chem 1988; 263: 18493-9.
72. Kroll M, Arenzana-Seisdedos F, Bachelerie F, Thomas D, Friguet B, Conconi M. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol 1999; 6: 689-98.
73. Hatabu T, Hagiwara M, Taguchi N, et al. Plasmodium falciparum: The fungal metabolite gliotoxin inhibits proteasome proteolytic activity and exerts a plasmodicidal effect on P. falciparum. Exp Parasitol 2006; 112: 179-83.
74. Fukuyama T, Kishi Y. A total synthesis of gliotoxin. J Am Chem Soc 1976; 98: 6723-4.
75. Fukuyama T, Nakatsuka S-I, Kishi Y. Total synthesis of gliotoxin, dehydrogliotoxin and hyalodendrin. Tetrahedron 1981; 37: 2045-78.
76. Tsukamoto S, Wakana T, Koimaru K, Yoshida T, Sato M, Ohta T. 7-hydroxy-3-(4-hydroxybenzyl)chroman and broussonin b: neurotrophic compounds, isolated from Anemarrhena asphodeloides BUNGE, function as proteasome inhibitors. Biol Pharm Bull 2005; 28: 1798-800.
77. Ronald RC, Wheeler CJ. Synthesis of the simple flavonoid broussonin A. J Org Chem 1984; 49: 1658-60.
78. Bode HB, Zeeck A. Structure and biosynthesis of kendomycin, a carbocyclic ansa-compound from Streptomyces. J Chem Soc Perkin 1 2000; 323-8.
79. Elnakady YA, Rohde M, Sasse F, et al. Evidence for the Mode of Action of the Highly Cytotoxic Streptomyces Polyketide Kendomycin. ChemBioChem 2007; 8: 1261-72.
80. Bahnck KB, Rychnovsky SD. Formal Synthesis of (-)-Kendomycin Featuring a Prins-Cyclization To Construct the Macrocycle. J Am Chem Soc 2008; 130: 13177-81.
81. Tanaka K, Watanabe M, Ishibashi K, Matsuyama H, Saikawa Y, Nakata M. Total Synthesis of Kendomycin Featuring Intramolecular Dötz Benzannulation. Org Lett 2010; 12: 1700-3.
82. Bicchielli D, Borguet Y, Delaude L, et al. Olefin Metathesis as Key Step in the Synthesis of Bioactive Compounds: Challenges in the Total Synthesis of (-)-Kendomycin. Curr Org Synth 2012; 9: 397-405.
83. Figueiredo-Pereira ME, Chen WE, Li J, Johdo O. The Antitumor Drug Aclacinomycin A, Which Inhibits the Degradation of Ubiquitinated Proteins, Shows Selectivity for the Chymotrypsin-like Activity of the Bovine Pituitary 20 S Proteasome. J Biol Chem 1996; 271: 16455-9.
84. Tsukamoto S, Yamanokuchi R, Yoshitomi M, et al. Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor. Bioorg Med Chem Lett 2010; 20: 3341-3.
85. Nazif T, Bogyo M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci U S A 2001; 98: 2967-72.
86. Kaiser M, Siciliano C, Assfalg-Machleidt I, Groll M, Milbradt AG, Moroder L. Synthesis of a TMC-95A Ketomethylene Analogue by Cyclization via Intramolecular Suzuki Coupling. Org Lett 2003; 5: 3435-7.
87. Berthelot A, Piguel S, Le Dour G, Vidal J. Synthesis of Macrocyclic Peptide Analogues of Proteasome Inhibitor TMC-95A. J Org Chem 2003; 68: 9835-8.
88. Basse N, Piguel S, Papapostolou D, et al. Linear TMC-95-Based Proteasome Inhibitors. J Med Chem 2007; 50: 2842-50.
89. Janetka JW, Raman P, Satyshur K, Flentke GR, Rich DH. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIVProtease Inhibitors. J Am Chem Soc 1997; 119: 441-2.
90. Kaiser M, Milbradt AG, Siciliano C, et al. TMC-95A Analogues with Endocyclic Biphenyl Ether Group as Proteasome Inhibitors. Chem Biodivers 2004; 1: 161-73.
91. Groll M, Götz M, Kaiser M, Weyher E, Moroder L. TMC-95-Based Inhibitor Design Provides Evidence for the Catalytic Versatility of the Proteasome. Chem Biol 2006; 13: 607-14.
92. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science 1995; 268: 726-31.
93. Groll M, Gallastegui N, Maréchal X, et al. 20S Proteasome Inhibition: Designing Noncovalent Linear Peptide Mimics of the Natural Product TMC-95A. ChemMedChem 2010; 5: 1701-5.
94. Loidl G, Musiol H-J, Groll M, Huber R, Moroder L. Synthesis of bivalent inhibitors of eucaryotic proteasomes. J Pept Sci 2000; 6: 36-46.
95. Loidl G, Groll M, Musiol H-J, Huber R, Moroder L. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci U S A 1999; 96: 5418-22.
96. Loidl G, Groll M, Musiol H-J, Ditzel L, Huber R, Moroder L. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem Biol 1999; 6: 197-204.
97. Maréchal X, Pujol A, Richy N, et al. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors. Eur J Med Chem 2012; 52: 322-7.
98. André P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 1998; 95: 13120-4.
99. Schmidtke G, Holzhütter H-G, Bogyo M, et al. How an Inhibitor of the HIV-I Protease Modulates Proteasome Activity. J Biol Chem 1999; 274: 35734-40.
100. Laurent N, Boüard S de, Guillamo J-S, et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 2004; 3: 129-36.
101. García-Echeverría C, Imbach P, France D, et al. A New Structural Class of Selective and Non-covalent Inhibitors of the Chymotrypsin- like Activity of the 20S Proteasome. Bioorg Med Chem Lett 2001; 11: 1317-9.
102. Furet P, Imbach P, Fürst P, et al. Modeling of the Binding Mode of a Non-covalent Inhibitor of the 20S Proteasome. Application to Structure-Based Analogue Design. Bioorg Med Chem Lett 2001; 11: 1321-4.
103. Furet P, Imbach P, Fuerst P, et al. Structure-Based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-Like activity of the human 20S proteasome. Bioorg Med Chem Lett 2002; 12: 1331-4.
104. Furet P, Imbach P, Noorani M, et al. Entry into a New Class of Potent Proteasome Inhibitors Having High Antiproliferative Activity by Structure-Based Design. J Med Chem 2004; 47: 4810-3.
105. Lum RT, Nelson MG, Joly A, et al. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1- indanone dipeptide benzamides. Bioorg Med Chem Lett 1998; 8: 209-14.
106. Lum RT, Kerwar SS, Meyer SM, et al. A New Structural Class of Proteasome Inhibitors that Prevent NF-κB Activation. Biochem Pharmacol 1998; 55: 1391-7.
107. Blackburn C, Gigstad KM, Hales P, et al. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit. Biochem J 2010; 430: 461-76.
108. Blackburn C, Barrett C, Blank JL, et al. Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg Med Chem Lett 2010; 20: 6581-6.
109. Blackburn C, Barrett C, Blank JL, et al. Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as noncovalent inhibitors of the chymotrypsin-like activity of human 20S proteasome. Medchemcomm 2012; 3: 710-9.
110. Basse N, Papapostolou D, Pagano M, et al. Development of lipopeptides for inhibiting 20S proteasomes. Bioorg Med Chem Lett 2006; 16: 3277-81.
111. Reboud-Ravaux M, Bernard E, Papapostolou D, Vanderesse R, inventors; CNRS, Reboud-Ravaux M, Bernard E, Papapostolou D, Vanderesse R, assignees. Novel Proteasome Modulators. World Patent WO 2005/061530. 2005 Dec.
112. Bégué J-P, Bonnet-Delpon D. Bioorganic and Medicinal Chemistry of Fluorine. New York: Wiley 2007.
113. Ojima I, Ed. Fluorine in Medicinal Chemistry and Chemical Biology. New York: Wiley 2009.
114. O’Hagan D. Fluorine in health care: Organofluorine containing blockbuster drugs. J Fluor Chem 2010; 131: 1071-81.
115. Manam RR, McArthur KA, Chao T-H, et al. Leaving Groups Prolong the Duration of 20S Proteasome Inhibition and Enhance the Potency of Salinosporamides. J Med Chem 2008; 51: 6711-24.
116. Groll M, McArthur KA, Macherla VR, Manam RR, Potts BC. Snapshots of the Fluorosalinosporamide/20S Complex Offer Mechanistic Insights for Fine Tuning Proteasome Inhibition. J Med Chem 2009; 52: 5420-8.
117. Geurink PP, Liu N, Spaans MP, et al. Incorporation of Fluorinated Phenylalanine Generates Highly Specific Inhibitor of Proteasome’s Chymotrypsin-like Sites. J Med Chem 2010; 53: 2319-23.
118. Formicola L, Maréchal X, Basse N, et al. Novel fluorinated pseudopeptides as proteasome inhibitors. Bioorg Med Chem Lett 2009; 19: 83-6.
119. Basse N, Montes M, Maréchal X, et al. Novel Organic Proteasome Inhibitors Identified by Virtual and in vitro Screening. J Med Chem 2010; 53: 509-13.
120. Kazi A, Lawrence H, Guida WC, et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 2009; 8: 1940-51.
121. Xu K, Xiao Z, Tang YB, et al. Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors. Bioorg Med Chem Lett 2012; 22: 2772-4.
122. Marzaro G, Gandin V, Marzano C, Guiotto A, Chilin A. Psoralenquinones as a Novel Class of Proteasome Inhibitors: Design, Synthesis and Biological Evaluation. ChemMedChem 2011; 6: 996-1000.
123. Ge Y, Kazi A, Marsilio F, et al. Discovery and Synthesis of Hydronaphthoquinones as Novel Proteasome Inhibitors. J Med Chem 2012; 55: 1978-98.
124. Gallastegui N, Beck P, Arciniega M, Huber R, Hillebrand S, Groll M. Hydroxyureas as Noncovalent Proteasome Inhibitors. Angew Chem Int Ed Engl 2012; 51: 247-9.
125. Yang H, Shi G, Dou QP. The Tumor Proteasome Is a Primary Target for the Natural Anticancer Compound Withaferin A Isolated from "Indian Winter Cherry". Mol Pharmacol 2007; 71: 426-37.
126. Huang L, Ho P, Chen C-H. Activation and inhibition of the proteasome by betulinic acid and its derivatives. FEBS Letters 2007; 581: 4955-9.
127. Qian K, Kim S-Y, Hung H-Y, Huang L, Chen C-H, Lee K-H. New betulinic acid derivatives as potent proteasome inhibitors. Bioorg Med Chem Lett 2011; 21: 5944-7.
128. Dougherty TJ, Dougherty TJ, Gomer CJ, et al. Photodynamic Therapy. J Natl Cancer Inst 1998; 90: 889-905.
129. Santoro AM, Lo Giudice MC, D’Urso A, Lauceri R, Purrello R, Milardi D. Cationic Porphyrins Are Reversible Proteasome Inhibitors. J Am Chem Soc 2012; 134: 10451-7.
130. Vispé S, Vandenberghe I, Robin M, et al. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem Pharmacol 2007; 73: 1863-72.